logo-loader
viewAchieve Life Sciences Inc

Achieve Life Sciences shares rise as data safety committee finds no issues with smoking cessation trial

The plant-based compound interacts with the brain’s nicotine receptors to reduce withdrawal symptoms

Cigarette butt
Stubbing it out ... the trial is looking at the smoking-cessation drug cytisinicline

Achieve Life Sciences Inc (NASDAQ:ACHV) shares swirled a bit higher Tuesday as the biotech revealed that the data safety monitoring committee (DSMC) had no issues with its trial of smoking-cessation drug cytisinicline.

The Phase 2b trial called ORCA-1 should continue, it said, while topline efficacy and safety data are expected by the end of the second quarter of 2019.

READ: Achieve Life Sciences shares rocket after a promising smoking-cessation drug trial

Cytisinicline is a plant-based alkaloid and has been an approved, branded product in Central and Eastern Europe for more than two decades to help combat nicotine addiction.

The data safety committee has reviewed the ORCA-1 data twice during the study, and has concluded following each review that there are no safety concerns for subjects or study conduct issues.

The trial is evaluating a 25-day treatment course of 1.5 mg or 3 mg doses of cytisinicline using either a declining titration schedule or three times daily. The trial is randomized and blinded to compare the effectiveness of the cytisinicline doses and schedules to respective placebo groups.

The primary efficacy endpoint is the overall reduction in the number of cigarettes smoked during the treatment period.

Shares in Achieve Life Sciences added 1.8% in New York to stand at $3.23

Quick facts: Achieve Life Sciences Inc

Price: 0.5214 USD

NASDAQ:ACHV
Market: NASDAQ
Market Cap: $13.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Alkane Resources hits almost 700 metres of mineralisation in...

Alkane Resources Ltd (ASX:ALK) managing director Nic Earner updates Proactive on follow-up drill results from the Boda prospect within the wider Northern Molong Porphyry Project (NMPP) near Orange in New South Wales. The drilling is part of a 5,000-metre diamond core drilling exploration...

15 hours, 44 minutes ago

2 min read